特利加压素和奥曲肽对肝硬化患者HVPG、BFV的影响

摘要：目的  研究特利加压素和奥曲肽对肝硬化（LC）患者肝静脉压力梯度（HVPG）及血流速度（BFV）的影响。方法  回顾性分析2014年5月-2016年4月该院66例LC合并静脉曲张患者的资料，按治疗方法分为特利加压素组、奥曲肽组、联合组，于治疗前后测定肝静脉楔压（WHVP）、肝静脉游离压（FHVP）、HVPG、BFV。结果  不同时间点的HVPG水平比较，差异有统计学意义（P <0.05）；联合组、奥曲肽组与特利加压素组的WHVP、HVPG比较，差异有统计学意义（P <0.05），联合组与奥曲肽组的HVPG水平比较，差异有统计学意义（P <0.05）；3组治疗后门静脉BFV比较，差异有统计学意义（P <0.05）；联合组与特利加压素组、奥曲肽组的FHVP、HVPG、门静脉BFV变化趋势比较，差异有统计学意义（P <0.05）。结论  特利加压素和奥曲肽均能降低HVPG，升高BFV，两者联合用药降低HVPG，升高BFV的作用优于单独用药。

Influence of Terlipressin and Octreotide on hepatic venous pressure gradient and blood flow velocity in patients with hepatic cirrhosis

 Abstract: Objective To study the influence of Terlipressin, Octreotide or their combination on hepatic venous pressure gradient (HVPG) and blood flow velocity (BFV) in patients with hepatic cirrhosis (LC). Methods The clinical data of 66 patients with hepatic cirrhosis and varicose veins from May 2014 to April 2016 were retrospectively analyzed. According to the treatment methods, they were divided into Terlipressin group (T group), Octreotide group (O group) and united group (L group). Before and after treatment, hepatic vein wedge pressure (WHVP), hepatic vein free pressure (FHVP), HVPG and portal vein BFV were measured. Results There were significant differences in HVPG levels at different time (P < 0.05). There were differences in WHVP and HVPG between the L group or the O group and the T group (P < 0.05). There was significant difference in HVPG between the L group and the O group (P < 0.05). There were differences in portal vein BFV after treatment among the three groups (P < 0.05). There were differences in the variation trends of FHVP, HVPG and portal vein BFV between the L group and the O group or the T group (P < 0.05). Conclusions Terlipressin and Octreotide can reduce HVPG and increase BFV. The effects of the combination of the two drugs are better than those of single medication.